Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PDD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: PDD. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-004109-27 Sponsor Protocol Number: 2.12.05 Start Date*: 2006-03-24
    Sponsor Name:Neuropsychiatric clinic
    Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies
    Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005346-37 Sponsor Protocol Number: F1D-MC-HGMR Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ...
    Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061345 Pervasive developmental disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004406-93 Sponsor Protocol Number: PDD-PC-01 Start Date*: 2007-05-29
    Sponsor Name:Klinikum der Universität München
    Full Title: Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom
    Medical condition: Patients with prostate carinoma who will undergo radical prostatectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003898-98 Sponsor Protocol Number: PDD_vs_WL-TURB_in_pazienti_con_NMIB Start Date*: 2013-11-28
    Sponsor Name:Ospedale San Raffaele
    Full Title: COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Medical condition: high grade non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001616-33 Sponsor Protocol Number: MEM-MD-91 Start Date*: 2012-11-14
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003484 Asperger's disorder PT
    14.1 10029205 - Nervous system disorders 10008520 Childhood autism LLT
    14.1 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001630-33 Sponsor Protocol Number: MEM-MD-69 Start Date*: 2012-11-14
    Sponsor Name:Forest Research Institute, Inc
    Full Title: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003484 Asperger's disorder PT
    14.1 10029205 - Nervous system disorders 10008520 Childhood autism LLT
    14.1 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IS (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000669-39 Sponsor Protocol Number: URU04 Start Date*: 2014-06-13
    Sponsor Name:Gregers Gautier Hermann
    Full Title: Endoscopic treatment of neoplasia in the upper urinary tract and the value of fluorescence guided endoscopic follow up.
    Medical condition: Urothelial tumors in the renal pelvis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10038517 Renal pelvis cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004760-31 Sponsor Protocol Number: CG/7657 Start Date*: 2007-04-17
    Sponsor Name:University of Dundee
    Full Title: Role and efficacy of topical 5-Aminolevulinic Acid (5-ALA) in Photodynamic detection (PDD) in determining malignant potential of oral lichen planus
    Medical condition: Oral Lichen Planus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10030983 Oral lichen planus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000559-15 Sponsor Protocol Number: FB2012 Start Date*: 2012-09-14
    Sponsor Name:FinnBladder
    Full Title: TREATMENT OF Ta BLADDER CANCER WITH HIGH RISK OF RECURRENCE – FLUORESCENCE CYSTOSCOPY WITH OPTIMIZED ADJUVANT MITOMYCIN-C
    Medical condition: bladder cancer (non-invasive Ta urothelial bladder cancer)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-001568-31 Sponsor Protocol Number: MEM-MD-68 Start Date*: 2012-11-14
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder ...
    Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003484 Asperger's disorder PT
    14.1 10029205 - Nervous system disorders 10008520 Childhood autism LLT
    14.1 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IT (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2015-000436-15 Sponsor Protocol Number: DD-study-3 Start Date*: 2015-05-18
    Sponsor Name:Aarhus Universitet
    Full Title: Photodynamic diagnosis (PDD) in flexible cystoscopy – a randomized study with focus on significant recurrence
    Medical condition: Patients with non muscle invasive bladder cancer in their first year after the diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001673-17 Sponsor Protocol Number: IRL752C002 Start Date*: 2017-08-22
    Sponsor Name:Integrative Research Laboratories AB
    Full Title: A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson’s Disease Dementia.
    Medical condition: Dementia in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014717 10012284 Dementia due to Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001523-39 Sponsor Protocol Number: D1050300 Start Date*: 2013-11-08
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006126-25 Sponsor Protocol Number: 06 038 Start Date*: 2007-06-08
    Sponsor Name:CNRS: VAN DER REST Michel
    Full Title: Emotional and Social deficits in Asperger syndrome
    Medical condition: We investigate the Asperger Syndrome, it's a pervasive developmental condition related to autism. It manifests in highly individual ways and can have both positive and negative effects on a person....
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001909-25 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder...
    Medical condition: Open treatment with atomoxetine for 10 weeks: •Week 1: 0,5 mg/kg/day in 1 or 2 doses. •Week 2 – 6: 1,2 mg/kg/day i 1 or 2 doses. •Week 6 – 8: Significant improvements: Continue on 1,2 mg/kg/day in ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000350-31 Sponsor Protocol Number: CENA713B2315 Start Date*: 2008-01-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with m...
    Medical condition: Mild to moderately severe dementia associated with Parkinson’s disease (PDD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012284 Dementia due to Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000309-60 Sponsor Protocol Number: 120101 Start Date*: 2016-03-30
    Sponsor Name:Göteborgs universitet
    Full Title: Biochemical and neuropsychological effects on Premenstrual Dysphoric Disorder after acute administration of escitalopram
    Medical condition: Premenstrual Dysphoric Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004335-36 Sponsor Protocol Number: ANAVEX2-73-PDD-001 Start Date*: 2018-07-04
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.
    Medical condition: Cognition in Parkinson’s Disease with dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001819-30 Sponsor Protocol Number: Sano2011 Start Date*: 2011-10-18
    Sponsor Name:Sanochemia Pharmazeutika AG
    Full Title: Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy (Hypericin PDD)
    Medical condition: Suspected non-muscle invasive (superficial) bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002875-81 Sponsor Protocol Number: NL58621.041.16 Start Date*: 2016-10-19
    Sponsor Name:UMC Utrecht
    Full Title: Bumetanide for the Autism Spectrum Clinical Effectiveness Trial
    Medical condition: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10008520 Childhood autism LLT
    20.0 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    20.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    20.0 10037175 - Psychiatric disorders 10061345 Pervasive developmental disorder LLT
    20.0 10037175 - Psychiatric disorders 10003805 Autism LLT
    20.0 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    20.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 01:11:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA